



CHINESE PATENT ISSUED IN BARD1 PATENT FAMILY FOR LUNG CANCER DIAGNOSIS

- Chinese Patent granted covering lung cancer diagnosis
- Protects a BARD1 autoantibody test for diagnosis of lung cancer in China

Melbourne, Australia, 24 December 2021: INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) announces that Chinese Patent ZL 201480071075.7 titled 'Lung Cancer Diagnosis' was issued by the Chinese Patent Office.

The issued ZL 201480071075.7 claims are directed towards methods for detecting antibodies to BARD1 peptides, methods for diagnosing lung cancer and kits for lung cancer diagnosis. The patent application was filed by BARD1AG SA (a fully owned subsidiary of INOVIQ Ltd) on 5 November 2014 and is due to expire on 5 February 2035.

CEO Dr Leeearne Hinch said: "This patent enforces intellectual property protection in China for a potential BARD1-Lung cancer test that detects autoantibodies associated with lung cancer. Patent family PCT/EP2014/073834 now has seven granted patents in Australia, China, Israel, Japan, Korea, Singapore and the USA."

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

COMPANY CONTACTS

Dr Leeearne Hinch
CEO
E lhinch@inoviq.com
M +61 400 414 416

Dr Geoff Cumming
Non-executive Chairman
E geoff.cumming@inoviq.com
M +61 417 203 021

Jane Lowe
IR Department
E jane.lowe@irdepartment.com.au
M +61 411 117 774

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising an innovative portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. For more information on INOVIQ, see www.inoviq.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.